Oncoinvent to Present at Cantor Fitzgerald Radiopharma Summit

Oncoinvent AS, a company in the clinical stage focused on advancing alpha emitter therapy for various solid tumors, has announced that its management team will be participating in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit. This event is scheduled for Monday, May 20, 2024, at 9:00 a.m. ET.

Oncoinvent AS is centered on developing groundbreaking radiopharmaceutical technology aimed at delivering precise alpha-emitting particles to target solid cancers effectively. The company's approach leverages its internal manufacturing and supply chain capabilities, ensuring a consistent clinical supply of radioisotopes. This enables the advancement of a pipeline of innovative products utilizing alpha particles, which are known for their higher Linear Energy Transfer (LET) radiation, with the potential to eradicate cancer cells.

The lead product from Oncoinvent, Radspherin®, is specifically designed to treat metastatic cancers within body cavities. Its versatile nature allows it to be used in the treatment of various cancer types. Currently, Radspherin® is undergoing two clinical studies aimed at treating peritoneal carcinomatosis resulting from ovarian cancer and colorectal cancer.

In summary, Oncoinvent AS is making significant strides in the field of radiopharmaceuticals by harnessing alpha emitter therapy to target and potentially eliminate solid tumors. The company's lead candidate, Radspherin®, shows promise in treating metastatic cancers within body cavities and is currently in clinical trials for ovarian and colorectal cancers.